A Web-Based Study of the Relationship of Duration of Insulin Pump Infusion Set Use and Fasting Blood Glucose Level in Adults with Type 1 Diabetes
Open accessAbstract
BACKGROUND: To evaluate the impact of infusion set use duration on glycemic control, we conducted an Internet-based study using the T1D Exchange's online patient community, Glu ( myGlu.org ). SUBJECTS AND METHODS: For 14 days, 243 electronically consented adults with type 1 diabetes (T1D) entered online that day's fasting blood glucose (FBG) level, the prior day's total daily insulin (TDI) dose, and whether the infusion set was changed. RESULTS: Mean duration of infusion set use was 3.0 days. Mean FBG level was higher with each successive day of infusion set use, increasing from 126 mg/dL on Day 1 to 133 mg/dL on Day 3 to 147 mg/dL on Day 5 (P<0.001). TDI dose did not vary with increased duration of infusion set use. CONCLUSIONS: Internet-based data collection was used to rapidly conduct the study at low cost. The results indicate that FBG levels increase with each additional day of insulin pump infusion set use.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Longer IIS wear duration >3 days has been associated with higher number of catheter-related adverse events, including hyperglycemia, site reactions, and silent occlusions.
“In addition, longer IIS wear duration >3 days has been associated with higher number of catheter-related adverse events, including hyperglycemia (blood glucose >250 mg/dL), site reactions, and ''silent occlusions.''7,12,17”
From Frequency and Detection of Insulin Infusion Site Failure in the Type 1 Diabetes Exchange Online Community (2023) · cites this paper as [17]
Table 2 (reproduced under Discussion; page unavailable) shows fasting glucose >250 mg/dL in 3% of observations on day 3, 4% on day 4, and 8% on day 5, supporting the hyperglycemia portion. The paper does not report higher numbers of site reactions or silent occlusions, or establish that the glucose readings were catheter-related adverse events. (LLM, conf=0.88)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Schmid, V., Hohberg, C., Borchert, M., Forst, T., & Pfützner, A. (2010) · Journal of Diabetes Science and Technology · doi:10.1177/193229681000400429 · Cited by 97 · see citing works
Flagged first, then by citations
Research works printed but not linked: 9
- Frid A, Hirsch L, Gaspar R, et al.: The Third Injection Technique Workshop in Athens (TITAN). Diabetes Metab 2010;36(Suppl 2):S19-S29.
- Heinemann L, Krinelke L: Insulin infusion set: the Achilles heel of continuous subcutaneous insulin infusion. J Diabetes Sci Technol 2012;6:954-964.
- Phillip M, Battelino T, Rodriguez H, et al.: Use of insulin pump therapy in the pediatric age-group: consensus statement from the European Society for Paediatric Endocrinology, the Lawson Wilkins Pediatric Endocrine Society, and the International Society for Pediatric and Adolescent Diabetes, endorsed by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2007;30:1653-1662.
- Thethi TK, Rao A, Kawji H, et al.: Consequences of delayed pump infusion line change in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infu- sion. J Diabetes Complications 2010;24:73-78.
- Beck RW, Tamborlane WV, Bergenstal RM, et al.: The T1D Exchange Clinic Registry. J Clin Endocrinol Metab 2012; 97:4383-4389.
- SAMPSON PERRIN ET AL. This article has been cited by: 1. Anneke Graf, Sybil A. McAuley, Catriona Sims, Johanna Ulloa, Alicia J. Jenkins, Gayane Voskanyan, David N. O'Neal. 2017. Moving Toward a Unified Platform for Insulin Delivery and Sensing of Inputs Relevant to an Artificial Pancreas. Journal of Diabetes Science and Technology 11:2, 308-314. [Crossref] · DOI
- Karlin Andrew W., Ly Trang T., Pyle Laura, Forlenza Gregory P., Messer Laurel, Wadwa R. Paul, DeSalvo Daniel J., Payne Sydney L., Hanes Sarah, Clinton Paula, Maahs David M., Buckingham Bruce. 2016. Duration of Infusion Set Survival in Lipohypertrophy Versus Nonlipohypertrophied Tissue in Patients with Type 1 Diabetes. Diabetes Technology & Therapeutics 18:7, 429-435. [Abstract] [Full Text HTML] [Full Text PDF] [Full Text PDF with Links] [Supplemental Material] · DOI · Paper page
- Heinemann Lutz. 2016. Insulin Infusion Sets: A Critical Reappraisal. Diabetes Technology & Therapeutics 18:5, 327-333. [Abstract] Full Text HTML] [Full Text PDF] [Full Text PDF with Links] · DOI
- Eda Cengiz, Bruce Bode, Michelle Van Name, William V Tamborlane. 2016. Moving toward the ideal insulin for insulin pumps. Expert Review of Medical Devices 13:1, 57-69. [Crossref · DOI · Paper page
Cited by
Sorted by citations
Pfützner, A., Sachsenheimer, D., Grenningloh, M., Heschel, M., Walther-Johannesen, L., Gharabli, R., & Klonoff, D. (2015) · Journal of Diabetes Science and Technology · doi:10.1177/1932296815604438 · Cited by 53 · see citing works
Hughes, M. S., Douvas, J. L., Layfield-Bryan, M., Blanco, L. E., Gray, J. C., Zapotoczny, G., Espinoza, J., Wilcox, J. H., & Lal, R. A. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0005 · Cited by 16 · see citing works
- Authors
- Sampson Perrin, A. J., Guzzetta, R. C., Miller, K. M., Foster, N. C., Lee, A., Lee, J. M., Block, J. M., Beck, R. W., & for the T1D Exchange Clinic Network
- Affiliations
- Jaeb Center for Health Research
- Jaeb Center for Health Research (US)
- Unitio
- University of Michigan (US)
- Stanford University (US)
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2015-05
- Volume
- 17
- Issue
- 5
- Pages
- 307-310
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W1860377209
- Cited by
- 19
- References
- 1
- Citations by year
- 2024: 2 · 2023: 5 · 2022: 1 · 2020: 2 · 2019: 2 · 2018: 2 · 2016: 3 · 2015: 2
- FWCI
- 2.03
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Locations
- Diabetes Technology & Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Deep Blue (University of Michigan) (submittedVersion)
- Funders
- Leona M. and Harry B. Helmsley Charitable Trust
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Physical Sciences › Engineering › Biomedical Engineering › Intravenous Infusion Technology and Safety
- Keywords
- type 1 diabetes, insulin pump therapy, fasting blood glucose, glycemic control, total daily insulin dose, online data collection, online patient communities, T1D Exchange
- MeSH terms
- Adolescent, Adult, Blood Glucose, Data Collection, Diabetes Mellitus, Type 1, Dose-Response Relationship, Drug, Fasting, Feasibility Studies, Female, Humans, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Male, Middle Aged, Surveys and Questionnaires, Time Factors, Internet, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
